ENXTBR:OXUR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Oxurion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OXUR has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.2%

OXUR

7.3%

BE Biotechs

10.1%

BE Market


1 Year Return

-25.4%

OXUR

80.1%

BE Biotechs

-13.2%

BE Market

Return vs Industry: OXUR underperformed the Belgian Biotechs industry which returned 79.1% over the past year.

Return vs Market: OXUR underperformed the Belgian Market which returned -16.7% over the past year.


Shareholder returns

OXURIndustryMarket
7 Day4.2%7.3%10.1%
30 Day-3.9%48.3%13.9%
90 Day-5.6%49.8%1.2%
1 Year-25.4%-25.4%80.1%80.1%-12.1%-13.2%
3 Year-15.3%-15.3%379.2%379.2%-22.1%-26.6%
5 Year-48.4%-48.4%331.0%331.0%-17.6%-26.3%

Price Volatility Vs. Market

How volatile is Oxurion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oxurion undervalued compared to its fair value and its price relative to the market?

1.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OXUR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OXUR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OXUR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OXUR is unprofitable, so we can't compare its PE Ratio to the Belgian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OXUR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OXUR is good value based on its PB Ratio (2x) compared to the BE Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Oxurion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-20.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXUR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OXUR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OXUR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OXUR's revenue (75.6% per year) is forecast to grow faster than the Belgian market (2.8% per year).

High Growth Revenue: OXUR's revenue (75.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OXUR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Oxurion performed over the past 5 years?

7.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OXUR is currently unprofitable.

Growing Profit Margin: OXUR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OXUR is unprofitable, but has reduced losses over the past 5 years at a rate of 7.6% per year.

Accelerating Growth: Unable to compare OXUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OXUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: OXUR has a negative Return on Equity (-97.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Oxurion's financial position?


Financial Position Analysis

Short Term Liabilities: OXUR's short term assets (€57.0M) exceed its short term liabilities (€10.4M).

Long Term Liabilities: OXUR's short term assets (€57.0M) exceed its long term liabilities (€1.3M).


Debt to Equity History and Analysis

Debt Level: OXUR is debt free.

Reducing Debt: OXUR has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OXUR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OXUR has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 9.9% each year.


Next Steps

Dividend

What is Oxurion's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OXUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OXUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OXUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OXUR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OXUR's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Patrik De Haes

11.75yrs

Tenure

€557,000

Compensation

Dr. Patrik De Haes, ViBio, BVBA, MD, has been the Chief Executive Officer of ThromboGenics NV since September 1, 2008. Dr. De Haes serves as an Executive Director of ThromboGenics NV. Dr. Haes serves as Ex ...


CEO Compensation Analysis

Compensation vs Market: Patrik's total compensation ($USD630.95K) is above average for companies of similar size in the Belgian market ($USD446.72K).

Compensation vs Earnings: Patrik's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Patrik De Haes
CEO, Acting CMO & Executive Director11.75yrs€557.00kno data
Dominique Vanfleteren
Chief Financial Officer5.42yrsno datano data
Jean Feyen
Chief Scientific Officerno datano datano data
Wouter Piepers
Global Head of Corporate Communications & Investor Relationsno datano datano data
Julie Binon
Head of HRno datano datano data
Andy De Deene
Global Head of Developmentno datano datano data
Ove Pedersen
Head of Product Supplyno datano datano data
Marc Denayer
Global Head of Drug Safety & Medical Affairs3.83yrsno datano data
Vinciane Vangeersdaele
Chief Commercial Officer2.58yrsno datano data

4.6yrs

Average Tenure

Experienced Management: OXUR's management team is considered experienced (4.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Patrik De Haes
CEO, Acting CMO & Executive Director11.75yrs€557.00kno data
Adrienne Graves
Non-Executive Independent Director1.67yrs€34.00kno data
Baron Vlerick
Non-Executive Independent Director4.92yrs€36.00k6.07% 6.3m
David Guyer
Non-Executive Director6.5yrs€69.00kno data
Thomas Clay
Independent Chairman3yrs€60.00k8.78% 9.1m
Emmanuele Attout
Non-Executive Independent Director5.08yrs€42.00kno data

4.9yrs

Average Tenure

61.5yo

Average Age

Experienced Board: OXUR's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Oxurion NV's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oxurion NV
  • Ticker: OXUR
  • Exchange: ENXTBR
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €103.388m
  • Shares outstanding: 38.29m
  • Website: https://www.oxurion.com

Number of Employees


Location

  • Oxurion NV
  • Gaston Geenslaan 1
  • Leuven
  • Flemish Brabant
  • 3001
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OXURENXTBR (Euronext Brussels)YesOrdinary Bearer SharesBEEURJul 2006
0G99LSE (London Stock Exchange)YesOrdinary Bearer SharesGBEURJul 2006
TBGN.FOTCPK (Pink Sheets LLC)YesOrdinary Bearer SharesUSUSDJul 2006
TG4DB (Deutsche Boerse AG)YesOrdinary Bearer SharesDEEURJul 2006

Biography

Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases and cancer in Belgium and internationally. Its lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of DME that has completed phase 1 clinical trial; THR-687 an integrin antagonist to treat patients with a diabetic eye disease that has completed phase 1 clinical trial; and TB-403, an anti- placental growth factor for the treatment of medulloblastoma, a pediatric malignant brain tumor. It has collaboration agreements with BioInvent International AB, Bicycle Therapeutics, Parexel, INC Research, and Galapagos. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 21:38
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.